Thyrotropin releasing hormone (TRH): DOPA potentiation and biogenic amine studies.
The present study in mice demonstrated the TRH when administered over 5 days remained active in the Everett Dopamine Potentiation Test. No evidence of tolerance was observed. In fact, an accumulative effect of TRH appeared to take place. Ablation of the adrenals, ovaries, testes, pineal, spleen, parathyroid, one kidney, or thymus did disrupt this behavioral potentiation of dopamine by TRH. TRH was found to potentiate the effects of imipramine. T3, T4, and TSH were found to be active in the DOPA potentiating test. No overt toxicity was observed between TRH and pargyline or between TRH and DOPA. Toxicity was seen only when all three agents were used together. TRH was found active in young and old mice. TRH was also found active in potentiating the central effects of serotonin. Biogenic amine brain levels in mice were not altered by TRH when administered for five days. Alpha-methyl-p-tyrosine reduced the activity of TRH in the dopamine potentiation test, suggesting dopaminergic mechanisms are involved by a direct receptor interaction.
D006916:5-Hydroxytryptophan / Q000494:pharmacology; D000375:Aging; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001679:Biogenic Amines / Q000378:metabolism*; D001921:Brain / Q000378:metabolism; D002369:Castration; D004295:Dihydroxyphenylalanine / Q000494:pharmacology*; D004357:Drug Synergism; D005260:Female; D007099:Imipramine / Q000494:pharmacology; D008297:Male; D008781:Methyltyrosines / Q000494:pharmacology; D051379:Mice; D010053:Ovary / Q000502:physiology; D010293:Pargyline / Q000494:pharmacology; D012701:Serotonin / Q000494:pharmacology; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology*
D001679:Biogenic Amines; D008781:Methyltyrosines; D012701:Serotonin; D013973:Thyrotropin-Releasing Hormone; D004295:Dihydroxyphenylalanine; D010293:Pargyline; D006916:5-Hydroxytryptophan; D007099:Imipramine